Trial Condition(s):
BAY94-9027 PK study comparing to another long acting product
19096
Not Available
The purpose of this study is to compare the pharmacokinetics of BAY94-9027 and Elocta after intravenous administration.
- Males, age 18 to 65 years. - Subjects with Severe Hemophilia A with a documented plasma FVIII level of < 1% - ≥ 150 exposure days with FVIII concentrate(s) as supported by medical records
- Evidence of current or past inhibitor antibody: - History of any congenital or acquired coagulation disorders other than hemophilia A. - Platelet count <75,000/mm*3. - Abnormal renal function (serum creatinine >2 x the upper limit of the normal range). - Active liver disease verified by medical history or persistently elevated alanine aminotransferase or aspartate aminotransferase >5 x the upper limit of the normal range or severe liver disease as evidenced by, but not limited to any of the following: International Normalized Ratio >1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.
Locations | |
---|---|
Locations SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD Sofia, Bulgaria, 1756 | Contact Us: E-mail: [email protected] Phone: (+) 1-888-8422937 |
Single dose, open label, randomized, crossover study in subjects with severe hemophilia A comparing pharmacokinetic parameters of BAY 94 9027 and Elocta
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Basic Science
Allocation:
Randomized
Blinding:
N/A
Assignment:
Crossover Assignment
Trial Arms:
2